{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.65 vs. cons $1.60",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$11.91B vs. cons $11.86B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Eliquis revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$4.05B vs. cons $4.00B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$6.35 midpoint ($6.20-$6.50) vs. cons $6.34 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$47.30B midpoint ($46.80B-$47.80B) vs. cons $47.30B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Eliquis worldwide revenue growth guidance",
      "prediction": "BETTER",
      "answer": "guide ~12.5% midpoint (10%-15%) vs. cons 12.0% (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.0,
  "day5_path": "FADE",
  "day5_rationale": "The EPS beat and modest guidance improvement should support the initial reaction, but the FY2026 guide midpoint remains approximately at the ~$6.34 consensus and provides limited revision upside. As analysts roll forward, accelerating legacy-product erosion and mix pressure are likely to restrain 2027 estimates, causing part of the day-1 gain to fade.",
  "day5_confidence": "MEDIUM"
}